-
Mercados
athexgroup.grAthens Exchange GroupRead moreTogether for a unified, stronger European capital market.
-
Acções
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Índices
A milestone in a decade of transformationEuronext joins the CAC 40®Read moreAs of 22 September 2025, Euronext has officially joined the CAC 40®, France’s flagship blue-chip index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fundos
-
Obrigações
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Warrants & Certificados
-
Derivados
Where European Government Bonds Meet the FutureTrade Mini Bond FuturesRead moreTrade mini bond futures on main European government bonds
-
Matérias-Primas
- Vista global
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Dairy derivatives
- Salmon derivatives
- Container Freight Futures
- Entrega e liquidação
- Especificações e disposições
- Commitments of Traders (CoT) report
- Commodity brokers
Take control of unpredictable dairy pricesEuropean Dairy DerivativesRead moreFutures and options on butter and skimmed milk powder now trading.
-
Recursos
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Sofinnova closes €725 million fund to back European biotech expansion
By Bhanvi Satija
LONDON, Nov 16 (Reuters) - Life sciences investment firm Sofinnova Partners said on Monday it has closed a second crossover fund at €725 million ($799 million), above its original target, to back European biotechs that are seeking to compete globally.
A crossover fund typically invests in private companies approaching commercialisation or public listings, bridging the gap between venture capital and public-market investing.
The raise comes at a time when drugmakers are pushing European governments to increase spending on medicines, faster trials and other policies that would prevent the region from losing ground to the US and China.
At the same time, cash-strapped governments in Europe are under pressure to rethink how they pay for innovative medicines.
Europe has outstanding science and companies, said Kinam Hong, a partner at Sofinnova, told Reuters in an interview.
"It doesn’t have an innovation gap, but it really has a financing growth capital problem," he said.
Hong said the fund, called Crossover II, is the biggest ever for the firm and will focus on European biotechs and medtech companies looking to commercialise their medicines or devices, with some selective investments in the US and elsewhere.
Through the fund, Sofinnova expects to back about 15 companies and has already invested in rare-disease biotech Hemab Therapeutics, multiple myeloma drug developer CellCentric and Neurent Medical, a chronic rhinitis device maker.
Hong said the firm plans to be an active investor, helping companies with leadership, trials and listings. He added that the aim is to build companies for "successful longevity" even without mergers and acquisitions.
The firm's first Crossover fund had backed Amolyt Pharma, a developer of treatments for rare hormone disorders that was acquired by AstraZeneca, as well as the French biotech Abivax, which is developing an ulcerative colitis drug.
Sofinnova manages more than €4 billion ($4.4 billion) in assets across healthcare and sustainability.
($1 = 0.9073 euros)
(Reporting by Bhanvi Satija in London, Editing by Louise Heavens)
Find it fast
Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education